Recombinant human monoclonal antibody specific for human tumor necrosis factor (North China Pharmaceutical)

重组人源抗人肿瘤坏死因子（TNF-α）单克隆抗体（华北制药）

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRecombinant human monoclonal antibody specific for human tumor necrosis factor (North China Pharmaceutical)
Drug Alias Name重组人源抗人肿瘤坏死因子(TNF-α)单克隆抗体注射液（华北制药）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNorth China Pharmaceutical Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNcpc Genetech Biotechnology Co LtdNorth China Pharmaceutical Group New Drug R&D Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A